Compare IIIN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIN | IVVD |
|---|---|---|
| Founded | 1953 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 639.8M | 659.8M |
| IPO Year | N/A | 2021 |
| Metric | IIIN | IVVD |
|---|---|---|
| Price | $36.74 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 176.3K | ★ 3.6M |
| Earning Date | 01-15-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.06% | N/A |
| EPS Growth | ★ 146.12 | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | ★ $677,910,000.00 | $50,039,000.00 |
| Revenue This Year | $14.20 | $107.86 |
| Revenue Next Year | $6.82 | $146.53 |
| P/E Ratio | $15.07 | ★ N/A |
| Revenue Growth | 26.20 | ★ 332.71 |
| 52 Week Low | $22.49 | $0.46 |
| 52 Week High | $41.64 | $3.07 |
| Indicator | IIIN | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 68.36 | 35.13 |
| Support Level | $31.80 | $1.67 |
| Resistance Level | $34.36 | $1.96 |
| Average True Range (ATR) | 1.01 | 0.14 |
| MACD | 0.35 | -0.04 |
| Stochastic Oscillator | 100.00 | 11.11 |
Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.